Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
143.3 USD | -0.28% | -0.76% | -25.13% |
Apr. 08 | Sector Update: Health Care Stocks Flat to Higher Premarket Monday | MT |
Apr. 08 | Sector Update: Health Care | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 68% by 2026.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.13% | 18.12B | B | ||
+1.51% | 42.75B | B | ||
+8.57% | 41.34B | B- | ||
+49.22% | 41.61B | A | ||
-12.36% | 26.59B | C | ||
+8.92% | 25.49B | B- | ||
+29.17% | 12.24B | C+ | ||
-3.12% | 11.76B | C+ | ||
+6.35% | 11B | B+ | ||
-16.98% | 10.07B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALNY Stock
- Ratings Alnylam Pharmaceuticals, Inc.